Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

DBV Technologies (0QAJ) Share Price & Analysis

0QAJ Stock Chart & Stats

€1.71-€0.11(-6.06%)
At close: 12:00 AM GMT
€1.75€2€2.25€2.53 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
EUR 1.71 - EUR 1.82
52-Week Range
EUR 1.53 - EUR 4.46
Previous Close
EUR 1.82
Volume
N/A
Average Volume (3M)
11.20K
Market Cap
EUR 534.36M
Enterprise Value
EUR 809.09M
Total Cash (Recent Filing)
EUR 162.95M
Total Debt (Recent Filing)
EUR 21.83M
Price to Earnings (P/E)
―
Beta
0.08
Next Earnings
Mar 11, 2027 (Est.)
EPS Estimate
-0.04
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Regulatory Progress

Submitting the Viaskin Peanut BLA marks meaningful progress toward potential commercialization and moves DBV beyond purely clinical development. The planned toddler filing could broaden the addressable pediatric population, although regulatory review and approval remain necessary.

Focused Platform

A focused EPIT platform gives DBV a consistent technological foundation around food-allergy treatment rather than a scattered pipeline. If Viaskin Peanut advances successfully, the same platform could support future immune-mediated applications and deepen the company’s strategic value.

Low Leverage

Relatively low leverage limits the burden of debt service and reduces balance-sheet pressure compared with a highly indebted biotech. This provides some financial flexibility while DBV advances its regulatory program, even though it does not eliminate the need for additional funding.

Bears Say

Going-Concern Risk

Management’s going-concern warning indicates that DBV’s current resources may not support operations through the next year. Required financing could dilute shareholders, impose financing costs, or constrain development priorities if capital is not obtained on favorable terms.

Heavy Cash Burn

Deeply negative operating and free cash flow shows that DBV is consuming substantial capital rather than funding operations internally. Persistent burn increases dependence on external financing and can reduce strategic flexibility during regulatory review and launch preparation.

Weak Commercial Base

Very low and declining revenue relative to the size of losses demonstrates that DBV has not yet established meaningful operating leverage. Until a product is approved and commercialized, the company remains exposed to prolonged losses and continued funding requirements.

DBV Technologies News

0QAJ FAQ

What was DBV Technologies’s price range in the past 12 months?
DBV Technologies lowest share price was €1.53 and its highest was €4.46 in the past 12 months.
What is DBV Technologies’s market cap?
DBV Technologies’s market cap is €534.36M.
When is DBV Technologies’s upcoming earnings report date?
DBV Technologies’s next earnings report is estimated for Mar 11, 2027 (not yet confirmed), which is in 129 days.
How were DBV Technologies’s earnings last quarter?
DBV Technologies released its earnings results on Oct 28, 2026. The company reported -€0.025 earnings per share for the quarter, beating the consensus estimate of -€0.047 by €0.022.
Is DBV Technologies overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does DBV Technologies pay dividends?
DBV Technologies does not currently pay dividends.
What is DBV Technologies’s EPS estimate?
DBV Technologies’s EPS estimate is -0.04.
How many shares outstanding does DBV Technologies have?
DBV Technologies has 314,388,800 shares outstanding.
What happened to DBV Technologies’s price movement after its last earnings report?
DBV Technologies reported an EPS of -€0.025 in its last earnings report, beating expectations of -€0.047. Following the earnings report the stock price went down -3.816%.
Which hedge fund is a major shareholder of DBV Technologies?
Currently, no hedge funds are holding shares in GB:0QAJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology